Company news
Relay Therapeutics, Inc. (NASDAQ:RLAY) news
Relay Therapeutics, Inc. news releases on 6ix. Latest, Jan 8, 2024: Relay Therapeutics Announces $30 Million Private Placement Financing
Press releases — page 2
Relay Therapeutics Announces $30 Million Private Placement Financing
January 7, 2024
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 6, 2023
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 1, 2023
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
October 25, 2023
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
October 11, 2023
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 17, 2023
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 7, 2023
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
July 31, 2023
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
May 24, 2023
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
May 3, 2023
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
April 26, 2023
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
April 17, 2023
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
March 5, 2023
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 22, 2023
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 15, 2023
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 1, 2023
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 2, 2022
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
October 26, 2022
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
September 25, 2022
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
September 11, 2022
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
September 11, 2022
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
September 10, 2022
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
August 17, 2022
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 3, 2022
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
July 27, 2022
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
June 26, 2022
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
June 15, 2022
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
May 4, 2022
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
May 2, 2022
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
April 27, 2022
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 23, 2022
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 16, 2022
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
January 3, 2022
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
December 9, 2021
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 9, 2021
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 3, 2021
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
October 7, 2021
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
October 6, 2021
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
September 12, 2021
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results
August 11, 2021
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 4, 2021
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
May 13, 2021
Relay Therapeutics Reports First Quarter 2021 Financial Results
May 12, 2021
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
May 9, 2021
Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
May 4, 2021
Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O’Meara and Charles Ferté
May 2, 2021
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
April 15, 2021